Skip to McMaster Navigation Skip to Site Navigation Skip to main content
McMaster logo

Therapeutics & Diagnostics 14-019

Method for determining coagulation activation in whole blood

Schematic of Coagulation Activation.

Tech ID



S. Qiao
P. Gross

Patent Status

US Patent 10131932
EP Patent 3047033
CA Patent 2923764

Stage of Research

Proof of Principle available


Sunita Asrani
Associate Director
Business Development and Copyright


Measuring coagulation activation, including thrombin generation, is useful in a number of clinical conditions. McMaster researchers have developed a novel method and class of substrates to do this using whole blood, for instance from a finger prick, using conventional fluorescence equipment.


  • Generate a point-of-care thrombin generation curve in the absence of anticoagulants in whole blood. Thrombin generation curves are known to be altered in different disease states
  • This novel method can be used as a point-of-care test for the presence of novel oral anticoagulants (NOACs), namely rivaroxaban, apixaban, and dabigatran in blood
  • Detect disorders of coagulation at point-of-care
  • Screen for inhibitors of coagulation in whole blood


  • Ability to monitor thrombin generation in whole blood
  • Detect thrombin generation without a correction of alpha-2-macroglobulin bound thrombin
  • This invention allows one to detect for the presence of new oral anticoagulants in whole blood within 15 minutes of a finger-prick, which is a novel, unique and valuable feature. There is a great need to detect NOACs at the point-of-care in endoscopy suites, emergency rooms, dentist’s offices, pre-op settings, cardiologist’s offices and internal medicine or family medicine offices
  • Ability to detect presence of direct factor Xa and direct thrombin inhibitors
  • Point-of-care test

Hamilton Health Sciences, St. Joseph's Healthcare Hamilton and McMaster University logos.